Have you had atopic dermatitis (eczema) for at least 2 years? If so, you may be able to participate in a study to help determine how safe and effective a study drug, called nemolizumab, is in treating atopic dermatitis. Study participation may last up to 60 weeks and may involve up to 16 study visits. Compensation is provided.
IRB:20191494 - A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
MEET THE RESEARCHER
Laura Korb Ferris, MD, PhD, is Associate Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.